Home › Companies › GHRS

GH Research PLC

GHRS Lead: Phase 2 6 Biotech Distilled articles ↓

Neurology Women's Health Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (4 active programs)

GH001

mebufotenin · GH001-TRD-201

Treatment-Resistant Depression Phase 2 inhaled

mebufotenin

GH001

Bipolar II Disorder Phase 2 inhaled
Postpartum Depression Phase 2 inhaled

mebufotenin

GH002

Treatment-Resistant Depression Phase 1 intravenous

Biotech Distilled coverage (6)

2026-05-15 UPDATE: GH Research (GHRS) - The Bridging Gate Just Cleared (And a $200M ATM Joins the Party) 🔒 Paid
2026-04-29 UPDATE: GH Research (GHRS) - The Fortress Just Got Bigger (And They Used the Rip to Build It) 🔒 Paid
2026-04-27 UPDATE: GH Research (GHRS) - The White House Tailwind and a 54% Rip 🔒 Paid
2026-03-28 UPDATE: GH Research (GHRS) - Peer-Reviewed Receipts: GH001 Defies the STAR*D Paradigm 🔒 Paid
2026-03-07 UPDATE: GH Research (GHRS) - Q4/FY25 Update 🔒 Paid
2026-01-17 GH Research (GHRS): Scientific Deep Dive for GH001 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.